ArticleCancers2021

Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study).

Eriko Tokunaga et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.